<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00214643</url>
  </required_header>
  <id_info>
    <org_study_id>06/2005/FOS-CLIN/SP</org_study_id>
    <nct_id>NCT00214643</nct_id>
  </id_info>
  <brief_title>Efficacy of Fosmidomycin-Clindamycin for Treating Malaria in Gabonese Children</brief_title>
  <official_title>A Comparative Assessment of the Efficacy of Fosmidomycin-Clindamycin Versus Sulfadoxine-Pyrimethamine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Schweitzer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albert Schweitzer Hospital</source>
  <brief_summary>
    <textblock>
      There is a necessity for the development of new malaria drugs. Some antibiotics are also
      effective against malaria parasites. Fosmidomycin is an antibiotic that has been shown to be
      effective against malaria, although it cannot achieve a total cure in all patients. Previous
      small studies have shown that in combination with clindamycin, an commonly used antibiotic,
      it is highly effective and safe when given for three days, leading to a total cure in most
      patients. The current study will evaluate its efficacy in a larger population in Gabon, and
      compare its effect with the generally used drug, sulfadoxine-pyrimethamine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fosmidomycin-clindamycin (30 mg/kg and 10 mg/kg) given twice daily for three days is an
      effective and safe combination of antibiotics which demonstrated good activity against
      malaria parasite in previous phase II studies in African children. In this phase III trial,
      the efficacy and safety of the combination will be evaluated in African children with
      uncomplicated P. falciparum malaria. A single dose of sulfadoxine-pyrimethamine, the standard
      antimalarial in Gabon, is used as comparator.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date>July 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and parasitological cure rate by day 28</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the two treatments during the entire study period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite clearance time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever clearance time</measure>
  </secondary_outcome>
  <enrollment>160</enrollment>
  <condition>Malaria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosmidomycin</intervention_name>
    <description>30 mg/kg</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clindamycin</intervention_name>
    <description>10 mg/kg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Uncomplicated P. falciparum malaria

          -  P. falciparum asexual parasitaemia between 1,000/µL and 100,000/µL

          -  Body weight between 10 - 65 kg

          -  Ability to tolerate oral therapy

          -  Informed consent, oral assent of the child, if possible

          -  Residence in study area

        Exclusion Criteria:

          -  Adequate anti-malarial treatment within the previous 7 days

          -  Antibiotic treatment for the current infection

          -  Previous participation in this clinical trial

          -  Haemoglobin &lt; 7 g/dl

          -  Haematocrit &lt; 23 %

          -  Leucocyte count &gt; 15,000 /µL

          -  Mixed plasmodial infection

          -  Severe malaria (as defined by WHO)

          -  Any other severe underlying disease (cardiac, renal, hepatic diseases, malnutrition,
             known HIV infection)

          -  Concomitant disease masking assessment of response

          -  History of allergy or intolerance against trial medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saadou Issifou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Schweitzer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research Unit, Lambaréné</name>
      <address>
        <city>Lambaréné</city>
        <state>Moyen Ogooué</state>
        <zip>B.P. 118</zip>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gabon</country>
  </location_countries>
  <link>
    <url>http://www.malaria.org</url>
    <description>General information on malaria at the website of the Malaria International Foundation</description>
  </link>
  <link>
    <url>http://www.lambarene.org</url>
    <description>Homepage of the Medical Research Unit, Lambaréné</description>
  </link>
  <reference>
    <citation>Kuemmerle HP, Murakawa T, Sakamoto H, Sato N, Konishi T, De Santis F. Fosmidomycin, a new phosphonic acid antibiotic. Part II: 1. Human pharmacokinetics. 2. Preliminary early phase IIa clinical studies. Int J Clin Pharmacol Ther Toxicol. 1985 Oct;23(10):521-8.</citation>
    <PMID>4066076</PMID>
  </reference>
  <reference>
    <citation>Kuemmerle HP, Murakawa T, Soneoka K, Konishi T. Fosmidomycin: a new phosphonic acid antibiotic. Part I: Phase I tolerance studies. Int J Clin Pharmacol Ther Toxicol. 1985 Oct;23(10):515-20.</citation>
    <PMID>4066075</PMID>
  </reference>
  <reference>
    <citation>Rohmer M, Knani M, Simonin P, Sutter B, Sahm H. Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate. Biochem J. 1993 Oct 15;295 ( Pt 2):517-24.</citation>
    <PMID>8240251</PMID>
  </reference>
  <reference>
    <citation>Kuzuyama T, Shizimu T, Takashi S and Seto H. Fosmidomycin, a specific inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway of isoprenoid biosynthesis. Tetrahaedron Lett 1998;39:7913-6</citation>
  </reference>
  <reference>
    <citation>Zeidler J, Schwender J, Müller C, et al. Inhibition of the non-mevalonate 1-deoxy-D-xylulose-5-phosphate pathway of plant isoprenoid biosynthesis by fosmidomycin. Z Naturforsch 1998;53:980-6</citation>
  </reference>
  <reference>
    <citation>Lois LM, Campos N, Putra SR, Danielsen K, Rohmer M, Boronat A. Cloning and characterization of a gene from Escherichia coli encoding a transketolase-like enzyme that catalyzes the synthesis of D-1-deoxyxylulose 5-phosphate, a common precursor for isoprenoid, thiamin, and pyridoxol biosynthesis. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2105-10.</citation>
    <PMID>9482846</PMID>
  </reference>
  <reference>
    <citation>Takahashi S, Kuzuyama T, Watanabe H, Seto H. A 1-deoxy-D-xylulose 5-phosphate reductoisomerase catalyzing the formation of 2-C-methyl-D-erythritol 4-phosphate in an alternative nonmevalonate pathway for terpenoid biosynthesis. Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9879-84.</citation>
    <PMID>9707569</PMID>
  </reference>
  <reference>
    <citation>Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M, Türbachova I, Eberl M, Zeidler J, Lichtenthaler HK, Soldati D, Beck E. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science. 1999 Sep 3;285(5433):1573-6.</citation>
    <PMID>10477522</PMID>
  </reference>
  <reference>
    <citation>Köhler S, Delwiche CF, Denny PW, Tilney LG, Webster P, Wilson RJ, Palmer JD, Roos DS. A plastid of probable green algal origin in Apicomplexan parasites. Science. 1997 Mar 7;275(5305):1485-9.</citation>
    <PMID>9045615</PMID>
  </reference>
  <reference>
    <citation>Fichera ME, Roos DS. A plastid organelle as a drug target in apicomplexan parasites. Nature. 1997 Nov 27;390(6658):407-9.</citation>
    <PMID>9389481</PMID>
  </reference>
  <reference>
    <citation>Borrmann S, Adegnika AA, Matsiegui PB, Issifou S, Schindler A, Mawili-Mboumba DP, Baranek T, Wiesner J, Jomaa H, Kremsner PG. Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis. 2004 Mar 1;189(5):901-8. Epub 2004 Feb 16.</citation>
    <PMID>14976608</PMID>
  </reference>
  <reference>
    <citation>Borrmann S, Issifou S, Esser G, Adegnika AA, Ramharter M, Matsiegui PB, Oyakhirome S, Mawili-Mboumba DP, Missinou MA, Kun JF, Jomaa H, Kremsner PG. Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis. 2004 Nov 1;190(9):1534-40. Epub 2004 Sep 21.</citation>
    <PMID>15478056</PMID>
  </reference>
  <reference>
    <citation>Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, Marsh K. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet. 1999 Feb 20;353(9153):632-6.</citation>
    <PMID>10030329</PMID>
  </reference>
  <reference>
    <citation>Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, Alonso P. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001 May 12;357(9267):1471-7.</citation>
    <PMID>11377597</PMID>
  </reference>
  <reference>
    <citation>Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000 Apr;94 Suppl 1:S1-90. Review.</citation>
    <PMID>11103309</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <keyword>Malaria</keyword>
  <keyword>Fosmidomycin</keyword>
  <keyword>Clindamycin</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Gabon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Fosmidomycin</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

